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Abstract Background Community pharmacists play an
important role in supporting patients for optimal drug use.
Objective To assess the effectiveness of monitoring in
asthma patients with inhaled corticosteroids (ICS) on dis-
ease control. Setting Asthma patients using ICS were
invited from two intervention (IG) and two control phar-
macies (CG). Method Participating patients completed
questionnaires at the study start and at 6-month follow-up,
including the Control of Allergic Rhinitis and Asthma Test
(CARAT) questionnaire. IG patients completed the
CARAT questionnaire every 2 weeks and received coun-
selling on disease management, ICS adherence, and
inhalation technique when scores were suboptimal, dete-
riorating, or absent. For Turbuhaler users, additional elec-
tronic monitoring (EMI) was available, with daily alerts for
ICS intake. Main outcome measure As the primary out-
come, CARAT scores at follow-up were compared
between IG and CG using linear regression. As secondary
outcome, refill adherence was compared using logistic
regression. Results From March to July 2015, we enrolled
39 IG and 41 CG patients. At follow-up, CARAT scores
did not differ between IG and CG (-0.19; 95% confidence
interval [CI], -2.57 to 2.20), neither did patient numbers
with ICS adherence [80% (0.82; 95% CI, 0.28–2.37).
Among EMI users, CARAT scores did not differ, but ICS
adherence [80% showed a 4.52-fold increase (95% CI,
1.56–13.1) compared with EMI nonusers. Conclusion
Among community-dwelling asthma patients, pharmacist
monitoring did not affect CARAT scores, but EMI use
showed improved ICS refill adherence.
Keywords Adherence  Asthma  Inhalation corticosteroid
maintenance therapy  Netherlands  Pharmacotherapy 
Pharmacy practice research
Impacts on practice
• Dutch community pharmacists play a role in monitor-
ing asthma patients for effective use of maintenance
medication.
• The use of the CARAT questionnaire to report disease
control every 2 weeks is feasible in asthma patients.
• Electronic monitoring improves ICS adherence in
astma patients.
• Disease stability was not influenced by tailored phar-
macist interventions on CARAT scores every two
weeks compared to usual care.
Introduction
An estimated 235 million people worldwide suffer from
asthma [1]. Maintenance therapy with inhaled corticos-
teroids (ICS) has played a central role in gaining and
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maintaining asthma control [2]. Interventions by commu-
nity pharmacists reportedly improve inappropriate inhala-
tion techniques, asthma control, patient-reported asthma-
related functional status, asthma severity, and symptoms
[3].
At present, pharmacists usually intervene during dis-
pensing visits [4, 5]. However, some patients may develop
imperfect asthma control, and poorly adherent patients may
not show up for subsequent dispensing. Timely interven-
tions targeted at patients with suboptimal disease control
may be effective in preventing exacerbations and deterio-
rating disease control between dispensing visits [6–8]. To
promote such interventions, tools are needed to continu-
ously monitor the process of drug intake and disease con-
trol. Ideally, patients and pharmacists should cooperate in
monitoring symptoms and actively manage disease control.
The available tools for prospective monitoring include
questionnaires on asthma control and electronic devices
measuring drug intake [9–12]. One example of the former
is the Control of Allergic Rhinitis and Asthma Test
(CARAT) questionnaire, which has been validated for
disease control of asthma and allergic rhinitis [13–17]. The
use of medication can also be measured based on electronic
monitoring of the intake of inhalation medication (EMI);
that has been suggested as a well-validated means of
measuring patterns of medication use [10, 11, 18]. Elec-
tronic monitoring has been widely studied for many years
[19–23], and it was recently shown to have a positive
impact on the use of inhalation medication [10, 24].
Regular employment of the CARAT questionnaire for
patient-reported monitoring and continuous utilization of
EMI enable monitoring of patients’ disease control and
medication use. However, the usefulness of that informa-
tion toward providing timely, tailored interventions in
clinical practice is largely unknown. In theory, health-care
providers can apply an individualized, data-driven
approach for tailored interventions. For example, some
patients could be helped by simplification of the dosing
regimen or by practical advice linking medication intake to
robust daily habits. Conversely, patients with intentional
non-adherence could benefit from motivation and infor-
mation about the disease, drug effects, and side effects;
patients with a poor inhalation technique may benefit from
improved inhaler use [7].
Aim of the study
In this pilot study, we investigated the effects of tailored
pharmacists’ interventions on patients’ asthma control by
prospective monitoring with patient-reported CARAT
scores compared with a control group receiving usual care.
Secondary objectives were the effectiveness of the
intervention on ICS adherence and on the number of
exacerbations. All outcomes were additionally analysed
with respect to the use of EMI in a planned subgroup
analysis.
Ethics approval
The study protocol was approved by the Ethical Committee
of the Radboudumc Nijmegen (approval number,
2015-1569), and the trial was registered at The Netherlands
National Trial Register (identifier, NTR5063). All proce-
dures performed in studies involving human participants
were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the
1964 Helsinki declaration and its later amendments or
comparable ethical standards. Informed consent was




This clustered controlled clinical trial was conducted
between March 2015 and January 2016 in four community
pharmacies in a rural area of the southern Netherlands.
Dutch pharmacists have a professional and legal respon-
sibility for the drug treatment of their patients [25]. As
most patients in the Netherlands visit one community
pharmacy, pharmacists usually possess the complete
medication histories of their patients [26–28].
The four community pharmacies had comparable care
structures: they all worked according to a certified quality
management system and cooperated well with general
practitioners (GPs) in structured pharmacotherapy circles
(on average six GPs per pharmacy). Concealed from the
patients, two pharmacies were designated as an interven-
tion group (IG) with the intervention programme (see
below). We made this choice to achieve equal practice
procedures in each group. Patients in the two other phar-
macies received usual pharmaceutical care–control group
(CG).
Patient inclusion
During regular pharmacy visits or by telephone, patients
were invited to participate in this study when meeting the
following selection criteria according to their pharmacy
database: (1) age 18–60 years; and (2) current user of
asthma maintenance medication. The medication included
ICS or a combination of ICS and long-acting beta-agonist
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(LABA); the Anatomic Therapeutic Chemical (ATC)
codes were R03BA, R03AK06, and R03AK07 [29], with at
least two prescriptions of ICS in the previous 6 months. A
current diagnosis of asthma and no (con)current chronic
obstructive pulmonary disease was verified by information
from the patient and the GP. Patients were included if they
spoke, read, and wrote Dutch. Informed consent was
obtained from all individual participants included. The
follow-up lasted for 6 months after patient inclusion.
EMI could be used for inhalation medication with
budesonide and formoterol (Turbuhaler) [24]. The device
was connected by Bluetooth to an application on the
patient’s smartphone and registered every inhalation. The
application was provided at no expense for the patient, and
patients voluntarily shared their data with the pharmacist.
Data were registered in a safe manner and provided only to
the patient and pharmacist. Information on medication use
became visible in the application (for up to 7 days) and a
personal web portal (up to 30 days) for both the patient and
pharmacist. The application reminded patients twice daily
to take their medication. Both IG and CG patients were
eligible for this programme if they met additional inclusion
criteria: (1) at least two prescriptions of budesonide or
formoterol Turbuhaler (ATC code R03AK07) (26) in the
previous 6 months; (2) access to a smartphone; and (3)
possessed skills to use the Internet.
Interventions
Training of health-care professionals
IG pharmacists and pharmacy assistants received addi-
tional training on asthma symptoms, treatment, possible
side effects, and smoking cessation. Furthermore, they
underwent 3-h training in interviewing techniques, with a
focus on exploring a patient’s ambivalence or readiness for
behavioural change. They were also trained to give
inhalation instructions and to use the CARAT question-
naire for monitoring asthma control. Pharmacists and
assistants from all pharmacies received information about
the EMI; however, only IG pharmacists used the moni-
toring information of their patients.
Intake and counselling session
CG patients received standard care and checks on their
inhalation technique; instructions were provided only at
their own request. IG patients received an intake session as
a one-to-one private counselling session with a trained
pharmacist or pharmacy assistant. Depending on their
needs and health literacy during those sessions, patients
received tailored education on the following: asthma
pathophysiology (symptoms and triggers); self-
management (e.g. lifestyle advice); smoking cessation (if
the patient was a current smoker); and the effects of their
asthma medication. For this purpose, information from
official pharmacist guidelines on asthma and patient
counselling during dispensing were used [30, 31]. Different
elements of inhalation medication use were discussed, such
as dosing and time of intake, the importance of adherence
to maintenance therapy, and problems with adherence or
experienced side effects and their prevention (e.g. rinsing
the mouth after inhalation, good inhalation technique). In
addition, the inhalation technique was checked with the
patient using a demonstration inhaler unit.
Timely, tailored interventions based on CARAT scores
During follow-up, the CARAT questionnaire was freely
available for IG patients as a smartphone and tablet
application. IG patients were instructed to download the
application and received a reminder to complete and send
the score every 2 weeks to the pharmacist. Via their per-
sonal e-mail, patients received graphic results of the
CARAT scores they had provided; the results were pre-
sented as the scores for both domains (lower and upper
airways) and the total score, and were sent by e-mail every
2 weeks. This information offered additionally self-moni-
toring options and insights for the IG patients.
If a CARAT score was not received within 16 days, the
score signalled disease instability (total CARAT score
B10) [15, 16], or the CARAT score deteriorated substan-
tially (C4 points) [15, 16], the IG pharmacist contacted IG
patients by e-mail or phone to identify the reasons.
According to the patient’s individual situation, the phar-
macist offered a tailored intervention. For IG patients in the
EMI group, the pharmacist used the EMI data to check
actual drug use.
Measures and outcomes
Measurement of disease control by CARAT questionnaire
The primary outcome of the study was asthma control,
measured by the CARAT questionnaire, compared between
IG and CG patients. The CARAT is a 10-item question-
naire developed to measure disease control of asthma and
allergic rhinitis [13–16]. The first nine questions offer
scores of 0 (complete absence of control) to 3 points. The
last question on increased medication use the previous
week has three response options (‘never’ = 3 points, ‘less
than 7 days’ = 2 points, ‘more than 7 days’ = 0 points)
and an option ‘I do not take any additional medication to
control my asthma,’ which was also attributed 3 points.
The CARAT score was calculated as the sum of the scores
for all questions and ranged from 0 to 30 [14].
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Secondary outcomes
Secondary outcomes addressed the number of exacerba-
tions and differences in medication adherence to ICS,
measured by the Medication Adherence Report Scale
(MARS-5) and by ICS refill data. Exacerbations were
counted using pharmacy dispensing data of the Dutch
Foundation for Pharmaceutical Statistics (SFK) [32] as
well as 6 months prior to the study start and 6 months
during the study period. In accordance with prevailing
clinical practice guidelines, we defined an exacerbation as
treatment with a course of a systemic corticosteroid (ATC
codes H02AB06 and H02BA07) [29] at a dose of at least
20 mg or higher for 5–14 days [33].
IG and CG patients completed the MARS-5-question-
naire at the beginning and end of the study. The MARS-5
questionnaire is a five-item self-report measure of medi-
cation adherence for rating the frequency of different types
of non-adherent behaviour [34, 35]. We calculated medi-
cation adherence from ICS refill data as the proportion of
days covered (PDC) by maintenance therapy with ICS
[36]—whether or not in fixed combination with an LABA
(ATC codes R03BA, R03AK06, R03AK07) [29]—from
routinely collected dispensing data of the SFK. We cal-
culated PDC percentages for 6 months prior to the study
start and at study end for 6 months during the study period.
In a planned subgroup analysis, we additionally com-
pared all measures between patients with and without EMI.
Sample size
We calculated the minimal sample size for the ability to
simultaneously detect a difference of 4 points [16] in
CARAT scores at an assumed standard deviation (SD) of 7
and difference in medication adherence of 15% in medi-
cation possession rate (SD = 20%) between the study end
and start, with 80% power at the 5% two-sided significance
level. Allowing for a dropout rate of 5%, we aimed at
enrolling 80 patients [13, 14].
Statistical analysis
Using linear regression analysis, we compared the CARAT
scores and mean medication adherence at follow-up
between the IG and CG patients, adjusted for the subject’s
measurement at the study start in addition to age and sex.
As neither the PDC nor the MARS-5 scores and the number
of oral corticosteroid courses fulfilled the requirements for
linear regression analysis (e.g. normal distribution), we
used logistic regression analysis for dichotomized cut-off
models, adjusted for the subject’s age, sex, and status at the
study start. We performed all analyses using IBM Corp
SPSS statistics, Chicago IL, USA, version 23.
Results
In the four pharmacies, 198 patients were screened for
eligibility, of whom 155 (78.3%) met all the inclusion
criteria (Fig. 1). In all, 80 patients (52%) agreed to par-
ticipate: 41 in the CG and 39 in the IG. The two study
groups were comparable regarding baseline characteristics,
including type of inhaled corticosteroids (Table 1); how-
ever, the mean age of IG patients was higher than that of
CG patients: 44.95 versus 39.34 years; P = 0.015. The
trial was completed by 68 patients; 12 patients were lost to
follow-up, largely for unknown reasons.
Among the 39 IG patients, 27 completed all 13 mea-
surements during follow-up. Owing to deteriorating
CARAT scores, 44 interventions were performed in 24
(61.5%) of the IG patients, with a maximum of four
interventions for one patient (Table 2).
At baseline, the mean CARAT scores were comparable
between the IG (20.36 points) and CG (21.29 points). In
multivariate regression analysis, the total CARAT scores at
follow-up did not differ between the IG and CG (Table 3):
mean estimated difference, –0.19 for the total score; 95%
confidence interval (CI), -2.57 to 2.20). Likewise, the
CARAT scores for the upper airways (–0.22; 95% CI,
-1.01 to 1.44) and lower airways (-0.62; 95% CI, -2.30
to 1.06) did not vary. We observed no difference between
the groups for the outcomes for medication adherence: the
probability of having a period covered by drug use[80%
did not vary between IG and CG (Odds Ratio, OR 0.82;
95% CI, 0.28–2.37).
The probability of achieving a score[20 on the MARS-
5 questionnaire (28) at the study end did not differ between
the two groups (0.55; 95% CI, 0.15–2.05). Finally, no
differences between IG and CG were found for the number
of exacerbations, measured by oral corticoid courses.
A planned subgroup analysis was performed for the 39
patients with EMI comparedwith the 41without EMI. Those
groups did not differ in terms of baseline characteristics,
except for a higher mean age of EMI patients: 44.08 years
versus 40.17 years; P = 0.001 (Table 4). In the EMI sub-
group, refill adherence[80% showed a 4.52-fold increase:
95%CI, 1.56–13.1 compared with no EMI use.We observed
no differences among the other measures (Table 5).
Discussion
In this study, we found that additional timely, tailored
pharmacist interventions did not increase asthma control or
ICS adherence compared with usual care. With EMI, we
recorded effects on refill adherence but not on the CARAT
or MARS-5 scores.
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Though at first sight these results appear disappointing, a
number of mitigating considerations exist. First, this
investigation was established as a pilot study to determine
the usefulness and feasibility of patient-reported monitor-
ing in measuring asthma control over time. Some studies
have investigated community pharmacist interventions to
improve asthma control; however, disease control was
mainly assessed using the Asthma Control Questionnaire or
Asthma Control Test, not the CARAT questionnaire [2, 3].
The number of eligible patients willing to participate in the
present study was just sufficient to detect a difference in
CARAT scores of 4 points between the study groups; that
is considered a clinically relevant score, according to the
CARAT developers [16]. At baseline, little was known
about the CARAT scores of community-dwelling asthma
patients in primary care. Our study showed high CARAT
scores—an average of 21 points—for this population at
study start. Hitherto, CARAT scores have been measured
monthly, and little has been known about their develop-
ment over time. The measurement of CARAT scores every
2 weeks was feasible in the IG and enabled regular phar-
macist-patient contacts between dispensing visits.
ICS-users 18-60 years
Screened for eligibility (n=198)
IG (n=39)
Eligible (n=155)
Not meeting inclusion criteria (n=43)
- No daily use of ICS (n=34)
- Current COPD (n=4)
- No regular visitor of the pharmacy (n=2)
- Cognitive problems (n=3)
Declined to participate (n=64)
- Not interested (n=53)
- No response/not available (n=17)
- Stopped with inhalation medication (n=4)





- Lost to follow-up 
(unknown): n=3
Completed trial (n=19)







- Lost to follow-up 
(migration) n=1





Completed trial (n=16 )
- Lost to follow-up 
(unknown reasons): n=4
Fig. 1 Flowchart participants during the study
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Table 1 Baseline characteristics
Parameter Intervention group (n = 39) Control group (n = 41)
Female sex [n (%)] 23 (59.0) 27 (65.9)
Age [years; mean (SD)] 44.95 (8.43) 39.34 (11.48)
Asthma, duration [years; mean (SD)] 23.9 (17.2) 20.9 (14.3)
Number of exacerbations treated by oral corticosteroid
courses 6 months before inclusion [mean (range)]
0.13 (0; 4) 0.02 (0; 1)
Smoking status:
Current [n (%)] 9 (22.5) 4 (9.8)
Earlier [n (%)] 8 (20.0) 12 (29.3)
Never [n (%)] 22 (55.0) 24 (58.5)
Electronic monitoring [n (%)] 19 (48.7) 20 (48.8)
CARAT total score [points (95% CI)] 20.36 (17.96–22.76) 21.29 (19.43–23.15)
CARAT upper airways score [points (95% CI)] 7.46 (6.22–8.70) 8.27 (7.26–9.27)
CARAT lower airways scores [points (95% CI)] 12.90 (11.24–14.56) 13.02 (11.74–14.31)
MARS-5 score [points (95% CI)] 20.79 (19.76–21.83) 21.22 (20.05–22.39)
Adherence ICS with dispensing data
[% PDC (95% CI)]
72.58 (65.46–79.70) 84.73 (77.57–91.88)
Table 2 Pharmacist interventions
Situation Pharmacist intervention Frequency
Decreased score on CARAT-domain upper airways Inquire about actual hay fever complaints and recommended the use
of an oral, ocular or nasal antihistamines or nasal corticosteroids
32 times
Low adherence scores Tailored advice to eventual barriers to chronic drug use or fear of ICS
side effects or to patients’ poor knowledge of asthma disease.
Discuss the importance of medication adherence
4 times
CARAT-score decreased substantially, possible overuse of
short acting beta agonists (SABA, use of C 3 times a
week)
Contact with patient to explore actual symptoms and possible reasons.
Invitation for visiting the pharmacy for a check of the inhalation
technique. Contact with prescriber to discuss switch of medication
(e.g. another nasal corticosteroid)
4 times
Persisting symptoms, despite interventions and adherent
use of ICS
Referral to the general practitioner for evaluation of persisting
symptoms
2 times
CARAT-score B10; indicating a possible exacerbation Referral to the general practitioner for examination of a possible
exacerbation and prescription of rescue medication, if needed
2 times
Table 3 Differences in
outcome measures between
intervention and control group
at follow up
Outcome measure Difference
CARAT total score (95% CI)a -0.19 (-2.57 to 2.20)a
CARAT upper airways score (95% CI)a 0.22 (-1.01 to 1.44)
CARAT lower airways scores (95% CI)a -0.62 (-2.30 to 1.06)
Period covered by drug dispensings[80% (95% CI)b 0.82 (0.28–2.37)
MARS-5 score[ 20 (95% CI)b 0.55 (0.15–2.05)
At least one oral corticosteroid short courseb No corticosteroid short courses in control group
a Linear regression analysis, adjusted for age, sex and baseline score, CI = Confidence Interval)
b Logistic regression analysis, adjusted for age, sex and baseline score
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In the planned subgroup analysis for EMI, ICS refill
adherence[80% was 4.52-fold (95% CI, 1.56–13.1) that of
EMI non-users. When including only subjects with
CARAT scores below 23 points at the study start, the OR
of achieving higher CARAT scores at the study end was
2.87 (95% CI 0.61–13.6) for the EMI group compared with
the non-EMI group. This finding suggests that poor asthma
control due to underuse of maintenance therapy with ICS
may be improved more effectively in this population by
EMI than with a tailored pharmacist intervention.
Regarding the difficulty in demonstrating the effects of
tailored interventions on disease outcomes, the findings of
the present study are not unique: a recent investigation
about tailored counselling on health-related lifestyles in
cardiovascular diseases also reported no effect on the pri-
mary outcome [37]. This suggests that for asthma patients
in primary care, EMI may be sufficient for improving
medication adherence; however, the effects on disease
outcomes remain to be shown. Furthermore, selection bias
cannot be fully excluded in the present study as patients
voluntarily participated in the study and for EMI use if
suitable. In general however, in the Netherlands all
inhabitants are obliged to have a health care insurance,
which gives access to all asthma medications. Therefore we
do not expect selection bias from this cause for our
findings.
The absence of spirometric confirmation of the asthma
diagnosis could be considered a limitation. However,
pharmacists do not generally have access to such data.
Corresponding with clinical practice, an asthma diagnosis
was initially assumed from the use of asthma medication; it
was verified with the patient and information from the
registration of contraindications in the computer system of
the GP, if available. We did not dispose of information on
comorbidities. Although asthma patients included were
relatively young and patients’ age was comparable between
the groups, we cannot fully exclude that we might have
missed differences between the groups due to comorbidity.
With regard to exacerbations, the use of short-term corti-
costeroid courses was low in both groups. A sub-analysis
with pooled measures of both types of short-term courses
did not achieve statistical significance. Finally, the use of
EMI within both IG and CG groups may have influenced
our intervention. However, in further analysis, we did not
observe any interaction between the intervention and EMI
use (P = 0.11 for a multiplicative interaction term).
Table 4 Baseline characteristics for subgroups with and without EMI
Parameter EMI-group (n = 39) No EMI- group (n = 41)
Female sex [n (%)] 21 (53.8) 29 (70.1)
Age [years; mean (SD)] 44.08 (6.93) 40.17 (12.71)
Asthma, duration [years; mean (SD)] 23.50 (15.49) 21.32 (16.20)
Number of exacerbations treated by oral corticosteroid
courses 6 months before inclusion [mean (range)]
0.10 (0–2) 0.12 (0–1)
CARAT total score [points (95% CI)] 20.95 (18.62–23.27) 20.73 (18.78–22.68)
CARAT upper airways score [points (95% CI)] 8.00 (6.81–9.19) 7.76 (6.68–8.83)
CARAT lower airways scores [points (95% CI)] 12.95 (11.38–14.51) 12.98 (11.59–14.36)
MARS-5 score [points (95% CI)] 21.08 (19.97–22.18) 20.95 (19.84–22.06)
Adherence ICS with dispensing data [% PDC (95% CI)] 82.38 (75.47–89.28) 75.42 (67.74–83.08)
Table 5 Differences in
outcome measures compared
between patients with and
without electronic monitoring
device at follow up
Outcome measure Difference
CARAT total score (95% CI)a 1.49 (-0.82 to 3.80)
CARAT upper airways score (95% CI)a 0.95 (-0.20 to 2.10)
CARAT lower airways scores (95% CI)a 0.52 (-1.12 to 2.17)
Period covered by drug dispensing[ 80% (95% CI)b 4.52 (1.56–13.1)
MARS-5 score[20 (95% CI)b 2.13 (0.60–7.55)
At least one oral corticosteroid short courseb 3.40 (0.25–46.50
Statistically significant outcomes are printed in bold
a Linear regression analysis, adjusted for age, sex and baseline score
b Logistic regression analysis, adjusted for age, sex and baseline score
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Conclusion
Our results did not show an effect of tailored pharmacist
interventions on patient-reported disease control in a gen-
eral asthma population compared with usual care. To
support non-intentional non-adherence in this population,
EMI may be effective; however, that strategy needs to be
confirmed with greater patient numbers for a longer follow-
up period for clinical outcomes.
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